Price
CHART BY
Frequently asked questions
What is X4 Pharms's market capitalization?
The market capitalization of X4 Pharms is $104.26M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for X4 Pharms?
X4 Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.0854. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for X4 Pharms's stock?
Currently, 5 analysts cover X4 Pharms's stock, with a consensus target price of $3.048. Analyst ratings provide insights into the stock's expected performance.
What is X4 Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, X4 Pharms reported a revenue of $1.12M.
What is the EBITDA for X4 Pharms?
X4 Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$130.29M. EBITDA measures the company's overall financial performance.
What is the free cash flow of X4 Pharms?
X4 Pharms has a free cash flow of -$125.97M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does X4 Pharms have, and what sector and industry does it belong to?
X4 Pharms employs approximately 93 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of X4 Pharms's shares?
The free float of X4 Pharms is 117.85M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $104.26M
- EPS (TTM)
- -$0.0854
- Free Float
- 117.85M
- Revenue (TTM)
- $1.12M
- EBITDA (TTM)
- -$130.29M
- Free Cashflow (TTM)
- -$125.97M
Pricing
- 1D span
- $0.612$0.616
- 52W span
- $0.262$1.60
Analyst Ratings
The price target is $3.048 and the stock is covered by 5 analysts.
Buy
5
Hold
0
Sell
0
Information
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
- Employees
- 93
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US98420X1037
- Primary Ticker
- XFOR